News and updates — Page 13 of 15 — German Market Access

Who are the members of the G-BA?

The G-BA has 13 voting members forming the so-called plenum. The representatives of care providers are only entitled to vote on topics

Drugs that primarily aim to increase the quality of life are so-called “lifestyle” drugs. These are not covered by the SHI funds

At the time of launch in the German market, pharmaceutical companies are free to set the price for their product with a

Did you know OTC drugs are reimbursed in Germany in exceptional circumstances? OTC drugs are those that don’t need to be prescribed

Before a new diagnostic and treatment method can be offered and reimbursed in the outpatient sector, two important steps need to be

Registry-based RCT could provide important answers on the optimal treatments and their sequencing for RRMS, but a lack of reimbursement hinders these

After several years of discussions, the EU will start to conduct joint HTAs in 2024. This process will be organized and overseen

In the recent early benefit assessment of nivolumab, the G-BA not only accepted the submitted ITC, but this also resulted in a

The antiviral drug remdesivir (brand name: Veklury) has been the first drug targeting COVID-19, which has undergone an early benefit assessment. It

If the G-BA concludes its early benefit assessment with “No additional benefit (proven)” and the product falls into a reference price group,